Analyst Price Target is $44.50
▲ +5.85% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Anika Therapeutics in the last 3 months. The average price target is $44.50, with a high forecast of $46.00 and a low forecast of $43.00. The average price target represents a 5.85% upside from the last price of $42.04.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in Anika Therapeutics. This Buy consensus rating has held steady for over two years.
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.